Skyline Dx, Janssen Partner on Adverse Reaction Risk Test for Multiple Myeloma Drug | GenomeWeb

By Molika Ashford

Dutch molecular diagnostic developer Skyline Diagnostics will collaborate with Johnson & Johnson's Janssen Pharmaceuticals to develop a test to identify patients at increased risk of side effects from a Janssen drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.